Our paper titled “Development and characterization of a first-in-class adjustable-dose gene therapy system” was published in Gene. Remedium Bio and the Zou Lab announced the publication of preclinical data demonstrating the performance of the adjustable dose gene therapy platform – Prometheus™. Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. The system specifically targets adipocytes, with the delivered transgene remaining localized to the site of injection, while the secreted protein biodistributes to the general circulation. The expressed protein kinetics were demonstrated to be zero-order, minimizing potential side effects caused by concentration spikes and suboptimal efficacy at concentration troughs present in a number of current subcutaneously delivered protein therapies.

This work was conducted by Jared Lourie with guidance from and discussion with Kai Zou, Alexey Seregin, and Alex Goraltchouk, and the assistance of Judith M Hollander, H Grace Rosen, and Atsutaro J Fujishiro. Available at https://doi.org/10.1016/j.gene.2024.148500.